Lurasidone Pharmacokinetics in Chinese Psychiatric Inpatients with Valproate Impact

156 Chinese psychiatric inpatients contributed 212 serum concentration measurements for a population pharmacokinetic model of lurasidone. The model identified valproate co-medication and age as significant covariates, with valproate increasing drug clearance by 47.7%. This dataset, authored by Ye Yang and licensed CC-BY-4.0, supports the reevaluation of therapeutic drug monitoring targets for this population.

Use Cases

• Build population pharmacokinetic models based on therapeutic drug monitoring data.
• Simulate drug concentration profiles stratified by age and concomitant medication.
• Assess the impact of valproate co-medication on lurasidone clearance.
• Investigate the relationship between observed drug concentrations and established therapeutic reference ranges.

Strengths

• Includes 212 serum concentration measurements from 156 patients.
• Model results quantify a 47.7% increase in lurasidone clearance due to valproate co-administration.
• Analysis is specific to Chinese psychiatric inpatients, a defined demographic.

Limitations

• Row count and column-level documentation are unknown, limiting suitability assessment.
• The dataset is very small at 13.7 KB, indicating limited scope.
• Data may reflect geographic bias inherent to the single-center study.

Provenance

Source

figshare, authored by Ye Yang.

Collection Method

Routine therapeutic drug monitoring data analyzed via nonlinear mixed-effects modeling (NONMEM).

Freshness

Last updated 2026-05-12 05:26:57.

Geography

China (Chinese psychiatric inpatients).